Login to Your Account


Durect Corp., better known as a drug delivery firm, disclosed a successful phase I trial with DUR-928, described as an endogenous small-molecule new chemical entity that could work in metabolic diseases such as nonalcoholic fatty liver disease and NASH.

In 2012, the Agency for Healthcare Research and Quality (AHRQ) set out to develop the Registry of Patient Registries (RoPR) as a one-stop repository of information about patient registries focused on, but not exclusive to, U.S.-based registries.

Boehringer Ingelheim GmbH's clinical hold on the oral beta secretase inhibitor BI 1181181 for Alzheimer's disease because of skin reactions in some patients put a dent in shares of partner Vitae Pharmaceuticals Inc., but if worse comes to worse, the pair can move on to a different, structurally distinct candidate in the same class that's ready for testing.

More IN THE CLINIC Headlines

Cast Your Vote

Has biotech’s bubble burst?: